TECH · Bio-Techne

The thesis

Bio-Techne's shares are more likely to lag the S&P 500 over three months. They trade just under Merck KGaA's $73.00-per-share cash offer, which caps the gain, and receipt of the remaining regulatory approvals, which sets the payment date, settles the case. The company's quarterly filing of 6 November 2026 still points to a close in late 2026 or early 2027.

The shares closed at $72.84 on 12 November 2026, against a 52-week high of $72.88 set on 9 November 2026. Upside beyond the offer needs a competing or raised proposal, and none has been reported. Shareholders approved the merger on 23 September 2026, and neither the 6 November 2026 quarterly report nor the 3 November 2026 dividend notice named an approval or a closing date.

Bullish and bearish views on Bio-Techne Corp

The bull case on Bio-Techne Corp (TECH), in brief: shareholders approved the merger. The bear case: some regulatory approvals are still open.

Bull case

• Shareholders approved the merger. Bio-Techne's 23 September 2026 press release says holders voted to approve and adopt the merger agreement. The release gave no vote tally.
• The US antitrust waiting period has expired. The Hart-Scott-Rodino waiting period ended at 11:59 p.m. Eastern time on 18 September 2026, per the same release. Germany's Federal Cartel Office had already cleared the deal in its first-phase review.
• The business kept growing under the deal. Net sales for the quarter ended 30 September 2026 were $299.7 million, up about 5% from $286.6 million a year earlier, with organic revenue up 7%, per the 10-Q filed 6 November 2026 as summarised by Stock Titan. A healthy target supports Merck KGaA's incentive to complete.
• Merck KGaA carries the larger break fee. The merger agreement disclosed 26 June 2026 sets a $576.1 million reverse termination fee payable by Merck KGaA, against $230.5 million payable by Bio-Techne.

Bear case

• Some regulatory approvals are still open. Bio-Techne's 23 September 2026 release refers to "remaining required regulatory approvals" without naming them. Press coverage of that date lists clearances in several other jurisdictions as pending.
• The payoff is capped and timing is open. The company guides to a close toward the end of 2026 or in early 2027. The merger agreement's outside date is 25 March 2027, so a delay stretches the wait for the $73.00 payment.
• Reported earnings fell. Net earnings for the quarter ended 30 September 2026 were $28.3 million against $38.2 million a year earlier, and diluted earnings per share were $0.18 against $0.24, per the 10-Q. Panabee reports operating income fell 23% to $37 million as selling, general and administrative expense rose 15% to $134 million, which it attributes to the pending merger.
• Little visibility between filings. Bio-Techne holds no quarterly investor calls and gave no fiscal 2027 guidance while the deal is pending, per its 12 August 2026 fiscal fourth-quarter release.

Price setup

The shares closed at $72.84 on 12 November 2026, below the $73.00 offer and 0.1% below the 52-week high of $72.88 reached on 9 November 2026. The adjusted 50-day average was $72.53 and the 200-day average $63.25 as of that close. The 3-month change was 0.7%.

The 52-week closing low of $43.30 came on 15 May 2026, before the Merck KGaA offer was announced. Since the announcement the shares have held in a narrow band under the offer price. Closes from 5 November to 12 November 2026 ran between $72.66 and $72.84.

The conditional $0.08 quarterly dividend is paid only if the deal has not closed by the 13 November 2026 record date. It is small next to the $73.00 payout.

Recent SEC Form 4 filings show no open-market insider sales. They show share withholding for tax at $72.66 for the chief executive officer and the chief financial officer on 1 November 2026, an option exercise of 11,545 shares by the chief financial officer on the same date, and grants of 2,750 shares to each of six directors on 29 October 2026.

Catalysts ahead

• 23 November 2026: Scheduled payment date for the conditional $0.08 dividend. Payment confirms the deal had not closed by the record date.
• ~31 December 2026 (est.): Company-guided closing window begins (late 2026 or early 2027). Receipt of the remaining regulatory approvals sets the payment date, and the shares should converge on $73.00 as approvals arrive.
• 25 March 2027: Merger agreement outside date. If approvals have not arrived by then and no extension is invoked, either party could terminate, which would remove the $73.00 offer.

Elapsed catalysts

• 13 November 2026: Record date for the conditional $0.08 quarterly dividend. The dividend is paid only if the Merck KGaA deal has not closed by this date; an earlier close would show approvals arrived sooner than guided. (passed)

What would change the view

A daily close above $78.62, well over the $73.00 cash offer, which would show the market pricing a higher or competing bid and the shares leading the S&P 500. A raised or rival proposal for Bio-Techne would show the same.

What it trades with

With the price tied to a fixed cash offer, the shares move on deal news and not with life-science tools peers or the broader market. A sharp move in either direction would most likely come from a regulatory announcement or a change in Merck KGaA's position.